Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer
NCT00003327
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with recurrent or refractory head and neck cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2008
Locations: California Cancer Center, Fresno, California +19 locations
Conditions: Head and Neck Cancer
Register for Updates
Chemotherapy in Treating Patients With Metastatic Kidney Cancer
NCT00024388
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DHA-paclitaxel in treating patients who have locally advanced, metastatic, or unresectable kidney cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2008
Locations: Arizona Oncology Associates, Tucson, Arizona +6 locations
Conditions: Kidney Cancer
Register for Updates
DHA-Paclitaxel in Treating Patients With Metastatic Colorectal Cancer
NCT00024401
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DHA-paclitaxel in treating patients who have metastatic colorectal cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2008
Locations: Arizona Oncology Associates, Tucson, Arizona +5 locations
Conditions: Colorectal Cancer
Register for Updates
DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer
NCT00024414
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DHA-paclitaxel in treating patients who have metastatic prostate cancer that has not responded to hormone therapy.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/23/2008
Locations: Arizona Oncology Associates, Tucson, Arizona +7 locations
Conditions: Prostate Cancer
Register for Updates
Paclitaxel With or Without Carboplatin in Treating Women With Metastatic Breast Cancer
NCT00025688
Unknown
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if paclitaxel is more effective with or without carboplatin in treating stage IV breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of paclitaxel with or without carboplatin in treating women who have stage IV breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/23/2008
Locations: Highlands Oncology Group, Springdale, Arkansas +24 locations
Conditions: Breast Cancer
Register for Updates
A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833
NCT00001383
Completed
This is a dosage escalation study to estimate the maximum tolerated dose of drug resistance inhibitor PSC 833 given in combination with paclitaxel. Groups of 3 to 6 patients receive continuous-infusion paclitaxel for 5 days and oral PSC 833 for 6-7 days, following paclitaxel on the first course, then beginning 3 days prior to paclitaxel on subsequent courses. Stable and responding patients are re-treated every 21 days, with paclitaxel dose adjusted to maintain an absolute neutrophil count less... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/03/2008
Locations: National Cancer Institute (NCI), Bethesda, Maryland
Conditions: Breast Cancer, Cancer, Carcinoma, Renal Cell, Lymphoma, Ovarian Cancer
Register for Updates
A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients
NCT00001384
Completed
This is a pilot feasibility trial of AC (Adriamycin, cyclophosphamide) chemotherapy with G-CSF (filgrastim) followed by infusional Taxol (paclitaxel) as adjuvant treatment for patients with high risk stage II and stage III breast cancer. Cycles will be 14 days in duration. After 3 fourteen day cycles of AC with filgrastim, patients will be treated with 3 fourteen day cycles of 96 hour infusional paclitaxel. The goal of this study will be to assess the toxicity and feasibility of administering do... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/03/2008
Locations: National Cancer Institute (NCI), Bethesda, Maryland
Conditions: Breast Cancer, Breast Neoplasms
Register for Updates
Phase I and Pharmacokinetic Trial of Paclitaxel (Taxol) Given as a 3-Hour Infusion in Pediatric Patients With Refractory Malignancy
NCT00001387
Completed
The objective of this trial is to determine the maximum tolerated dose and the toxicities of paclitaxel given as a short hour infusion in children with refractory malignancy.
Gender:
ALL
Ages:
All
Trial Updated:
03/03/2008
Locations: National Cancer Institute (NCI), Bethesda, Maryland
Conditions: Neoplasms
Register for Updates
A Pilot Study of Paclitaxel With Radiation Therapy for Locally Advanced Head and Neck Cancer
NCT00001442
Completed
Radiotherapy plus Single-Agent Chemotherapy/Radiosensitization. Irradiation of tumor and involved nodes using 4-6 MV photons (brachytherapy allowed to boost primary tumor; electrons allowed to boost posterior neck and massive adenopathy); plus Paclitaxel (Bristol-Myers), Taxol, TAX, NSC-125973.
Gender:
ALL
Ages:
All
Trial Updated:
03/03/2008
Locations: National Cancer Institute (NCI), Bethesda, Maryland
Conditions: Head and Neck Neoplasm, Squamous Cell Carcinoma
Register for Updates
Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage III/IV and Relapsed NSCLC
NCT00001450
Completed
This is a Phase II study of paclitaxel (Taxol R) administered as a 96-hour (4 day) continuous infusion followed by a bolus of cisplatin for previously untreated patients with stage III/IV or relapsed non-small cell lung cancer (NSCLC). The goal of this phase II study is to determine the response rate of this infusional paclitaxel and bolus cisplatin regimen in patients with advanced NSCLC.
Gender:
ALL
Ages:
All
Trial Updated:
03/03/2008
Locations: National Cancer Institute (NCI), Bethesda, Maryland
Conditions: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Register for Updates
A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer
NCT00001498
Completed
Stage III patients may begin therapy prior to or following surgery. Patients with undrainable significant third space fluid collection (e.g., pleural effusions, ascites) are entered directly on Consolidation. Patients receive induction chemotherapy with methotrexate and fluorouracil every 2 weeks for 4 courses. Patients then receive two 3-week courses of consolidation therapy with cyclophosphamide, followed by daily granulocyte colony-stimulating factor until completion of leukapheresis. Patie... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/03/2008
Locations: National Cancer Institute (NCI), Bethesda, Maryland
Conditions: Breast Cancer, Breast Neoplasms
Register for Updates
Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer
NCT00001499
Completed
2-Drug Combination Chemotherapy Followed by Radiotherapy. Paclitaxel, TAX, NSC-125973; Cisplatin, CDDP, NSC-119875; followed by chest irradiation using 4-15 MV photons.
Gender:
ALL
Ages:
All
Trial Updated:
03/03/2008
Locations: National Cancer Institute (NCI), Bethesda, Maryland
Conditions: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Register for Updates